Please login to the form below

Not currently logged in
Email:
Password:

obeticholic acid

This page shows the latest obeticholic acid news and features for those working in and with pharma, biotech and healthcare.

Better together when buying medicines? Taking stock of the BeNeLuxA initiative

Better together when buying medicines? Taking stock of the BeNeLuxA initiative

was subsequently updated) for Vertex’s cystic fibrosis treatment Orkambi (lumacaftor/ivacaftor), Intercept’s Ocaliva (obeticholic acid) for primary biliary cholangitis and for Biogen’s Spinraza (nusinersen) for spinal muscular atrophy

Latest news

  • Gilead NASH drug clears mid-stage trial, but rivals are looming Gilead NASH drug clears mid-stage trial, but rivals are looming

    The new data shows Gilead’s drug is working as expected, but analysts said the results don’t look particularly robust when compared to Intercept Pharma’s Ocaliva (obeticholic acid), which ... Gilead has positioned GS-9674, a non-bile acid FXR, as

  • Novartis and Pfizer to collaborate on NASH combinations Novartis and Pfizer to collaborate on NASH combinations

    Novartis and Pfizer announced their collaboration yesterday, with the view to combining phase 1 and phase 2 assets in Pfizer’s pipeline with Novartis’ tropifexor, a non-bile acid, Farnesoid X ... Intercept’s Ocaliva (obeticholic acid, an FXR agonist

  • Intercept hit hard as FDA issues Ocaliva safety notice Intercept hit hard as FDA issues Ocaliva safety notice

    The US regulator issued a safety notice yesterday warning that the company's Ocaliva (obeticholic acid) for primary biliary cholangitis (PBC) had been linked to 19 deaths and 11 cases of ... the only approved PBC therapy - ursodeoxycholic acid (UDCA) or

  • BMS claims a win in mid-stage NASH trial BMS claims a win in mid-stage NASH trial

    elafibranor and Intercept's Ocaliva (obeticholic acid), which is already on the market for another indication (primary biliary cholangitis).

  • Intercept gets EU nod for rare liver disease therapy Intercept gets EU nod for rare liver disease therapy

    The European Medicines Agency (EMA) granted a conditional approval for Ocaliva (obeticholic acid) in combination with the only approved PBC therapy - ursodeoxycholic acid (UDCA) - in adult patients who can't tolerate

More from news
Approximately 5 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics